---
title: "Breakthrough in Fight Against Alzheimer's Disease: Researchers Discover Potential Benefits of Rapamycin"
url: https://noti.group/breakthrough-in-fight-against-alzheimer-s-disease-researchers/
language: en
publisher: "Noti Group"
section: "Health"
published: 2026-11-06T01:11:19.000Z
updated: 2026-11-06T14:34:10.292Z
id: 95ff13a4-de65-48fb-b0d2-47afa7863b7a
source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/11/261104084017.htm"
attribution: "Link to https://noti.group/breakthrough-in-fight-against-alzheimer-s-disease-researchers/ and name Noti Group when you quote or summarize this story."
---

# Breakthrough in Fight Against Alzheimer's Disease: Researchers Discover Potential Benefits of Rapamycin

Researchers at the University of Missouri have found that rapamycin, a medication typically prescribed to prevent organ transplant rejection, may help protect people at increased risk of developing Alzheimer's disease by improving blood flow in their brains.

A breakthrough in the fight against Alzheimer's disease has been reported by researchers at the University of Missouri, who have found that a commonly used medication may help protect people at increased risk of developing the condition.

The study focused on rapamycin, a drug typically prescribed to prevent organ transplant rejection, and its potential effects on blood flow in the brains of middle-aged adults carrying a gene variant linked to Alzheimer's disease. According to the research, rapamycin was found to improve blood flow in these individuals, which is crucial for maintaining brain health.

The discovery could have significant implications for addressing Alzheimer's risk long before memory problems appear, allowing scientists to develop strategies that target the condition early on. This aligns with the university's ongoing efforts to understand and potentially prevent the most common form of dementia.

A major focus of Lin's research is the APOE4 gene variant, which significantly increases a person's likelihood of developing Alzheimer's disease later in life. People carrying this variant can experience reduced blood flow in certain areas of the brain years before they begin having noticeable memory difficulties.

This reduction in circulation can occur so early that researchers believe it may serve as an important warning sign of increased Alzheimer's risk, highlighting the need for further investigation into its role in the development of the condition.

Researchers are exploring whether an existing medication can improve brain circulation and potentially reduce the risk of developing Alzheimer's disease.

The study focused on individuals carrying the APOE4 gene variant, which increases the likelihood of Alzheimer's in older age. Participants with this genetic predisposition showed a notable improvement in brain blood flow when given a low daily dose of rapamycin for four weeks.

This improvement was not seen in participants without the APOE4 gene variant, suggesting that rapamycin may have a specific benefit for those at higher risk of Alzheimer's due to their genetics.

Further investigation is needed to fully understand the potential benefits and mechanisms behind rapamycin's effects on brain circulation.

The study's results suggest that improved brain circulation may be a crucial factor in preventing or slowing down Alzheimer's disease, and further research is needed to fully understand this potential link.

Interestingly, the greatest benefits of improved brain circulation were seen among women who carried the APOE4 gene, which is known to increase the risk of developing Alzheimer's.

This finding is particularly significant because it highlights a key difference in how men and women respond to the treatment. In fact, nearly two-thirds of people living with Alzheimer's disease are women, making this subgroup an important area of focus for future research.

The study's emphasis on precision medicine is also noteworthy, as it suggests that individual characteristics such as genetics play a crucial role in determining which treatments may be most effective.

Collaborative research environments like the one at Mizzou's Roy Blunt NextGen Precision Health building are helping to advance discoveries and move them more quickly into human clinical studies.

The latest findings from a pilot study suggest that rapamycin may have the potential to delay or reduce the risk of Alzheimer's disease in individuals who are genetically vulnerable to the condition.

The research involved middle-aged participants who carried the APOE4 gene variant, which is known to increase the likelihood of developing Alzheimer's. The results showed that rapamycin increased cerebral blood flow and had a positive impact on various metabolic, inflammatory, and microbiome profiles in these individuals.

These promising early results provide an encouraging foundation for further investigation into the therapeutic potential of rapamycin in preventing or delaying Alzheimer's disease onset.

---
Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/11/261104084017.htm)  
Published by Noti Group: https://noti.group/breakthrough-in-fight-against-alzheimer-s-disease-researchers/